Esophagus sparing with IMRT in lung tumor irradiation: an EUD-based optimization technique.

PURPOSE The aim of this study was to evaluate (1) the use of generalized equivalent uniform dose (gEUD) to optimize dose escalation of lung tumors when the esophagus overlaps the planning target volume (PTV) and (2) the potential benefit of further dose escalation in only the part of the PTV that does not overlap the esophagus. METHODS AND MATERIALS The treatment-planning computed tomography (CT) scans of patients with primary lung tumors located in different regions of the left and right lung were used for the optimization of beamlet intensity modulated radiation therapy (IMRT) plans. In all cases, the PTV overlapped part of the esophagus. The dose in the PTV was maximized according to 7 different primary cost functions: 2 plans that made use of mean dose (MD) (the reference plan, in which the 95% isodose surface covered the PTV and a second plan that had no constraint on the minimum isodose), 3 plans based on maximizing gEUD for the whole PTV with ever increasing assumptions for tumor aggressiveness, and 2 plans that used different gEUD values in 2 simultaneous, overlapping target volumes (the whole PTV and the PTV minus esophagus). Beam arrangements and NTCP-based costlets for the organs at risk (OARs) were kept identical to the original conformal plan for each case. Regardless of optimization method, the relative ranking of the resulting plans was evaluated in terms of the absence of cold spots within the PTV and the final gEUD computed for the whole PTV. RESULTS Because the MD-optimized plans lacked a constraint on minimum PTV coverage, they resulted in cold spots that affected approximately 5% of the PTV volume. When optimizing over the whole PTV volume, gEUD-optimized plans resulted in higher equivalent uniform PTV doses than did the reference plan while still maintaining normal-tissue constraints. However, only under the assumption of extremely aggressive tumors could cold spots in the PTV be avoided. Generally, high-level overall results are obtained when optimization in the whole PTV is also associated with a second simultaneous optimization in the PTV minus overlapping portions of the esophagus. CONCLUSIONS Intensity modulated radiation therapy optimizations that utilize gEUD-based cost functions for the PTV and NTCP-based constraints for the OARs result in increased doses to large portions of the PTV in cases where the PTV overlaps the esophagus, while still maintaining (and confining to the overlap region) minimum dose coverage equivalent to the homogeneous PTV optimization cases.

[1]  M. Goitein,et al.  Fitting of normal tissue tolerance data to an analytic function. , 1991, International journal of radiation oncology, biology, physics.

[2]  John W Wong,et al.  Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL. , 2003, International journal of radiation oncology, biology, physics.

[3]  James M Balter,et al.  Daily targeting of intrahepatic tumors for radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[4]  M. Roach,et al.  Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. , 1999, International journal of radiation oncology, biology, physics.

[5]  H. Choy,et al.  Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R K Ten Haken,et al.  The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[7]  Avraham Eisbruch,et al.  Intensity-modulated radiation therapy (IMRT) for locally advanced paranasal sinus tumors: incorporating clinical decisions in the optimization process. , 2003, International journal of radiation oncology, biology, physics.

[8]  Kunihiko Kobayashi,et al.  Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. , 2004, Lung cancer.

[9]  Kai-Liang Wu,et al.  Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. , 2003, International journal of radiation oncology, biology, physics.

[10]  Joos V Lebesque,et al.  Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. , 2003, International journal of radiation oncology, biology, physics.

[11]  José Belderbos,et al.  Biology contributionComparing different NTCP models that predict the incidence of radiation pneumonitis , 2003 .

[12]  M. Socinski,et al.  Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.

[13]  C. Ling,et al.  Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer. , 2000, International journal of radiation oncology, biology, physics.

[14]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[15]  Indrin J Chetty,et al.  Photon beam relative dose validation of the DPM Monte Carlo code in lung-equivalent media. , 2003, Medical physics.

[16]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D L McShan,et al.  Is uniform target dose possible in IMRT plans in the head and neck? , 2002, International journal of radiation oncology, biology, physics.

[18]  Y. Ung,et al.  Reproducibility of lung tumor position and reduction of lung mass within the planning target volume using active breathing control (ABC). , 2003, International journal of radiation oncology, biology, physics.

[19]  J. Deasy Partial tumor boosts: even more attractive than theory predicts? , 2001, International journal of radiation oncology, biology, physics.

[20]  Joseph O Deasy,et al.  The generalized equivalent uniform dose function as a basis for intensity-modulated treatment planning. , 2002, Physics in medicine and biology.

[21]  G J Kutcher,et al.  Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. , 1999, International journal of radiation oncology, biology, physics.

[22]  W. Curran,et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[24]  A. Niemierko Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.

[25]  Marina A. Epelman,et al.  Costlets: A Generalized Approach to Cost Functions for Automated Optimization of IMRT Treatment Plans , 2005 .

[26]  M. Martel,et al.  Dose escalation for non-small cell lung cancer using conformal radiation therapy. , 1997, International journal of radiation oncology, biology, physics.

[27]  R. Komaki,et al.  A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. , 1998, International journal of radiation oncology, biology, physics.

[28]  J. Fowler,et al.  Selective boosting of tumor subvolumes. , 2000, International journal of radiation oncology, biology, physics.

[29]  C. Burman,et al.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. , 1989, International journal of radiation oncology, biology, physics.

[30]  C. Ling,et al.  Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. , 2000, Cancer journal.

[31]  D. Galetta,et al.  Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  A. Brugarolas,et al.  Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung. , 1999, American journal of clinical oncology.

[34]  Woo Sung Kim,et al.  Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[35]  J. Doroshow,et al.  Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C C Ling,et al.  The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. , 2000, International journal of radiation oncology, biology, physics.

[37]  R. Mohan,et al.  Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. , 2002, International journal of radiation oncology, biology, physics.

[38]  E. Tan,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. , 1999, Acta oncologica.

[39]  J. Lyman Complication Probability as Assessed from Dose-Volume Histograms , 1985 .

[40]  J. Wong,et al.  The use of active breathing control (ABC) to reduce margin for breathing motion. , 1999, International journal of radiation oncology, biology, physics.

[41]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[42]  J. Battista,et al.  A convolution method of calculating dose for 15-MV x rays. , 1985, Medical physics.

[43]  M. V. van Herk,et al.  Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[44]  H. Choy,et al.  Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  T. Bortfeld,et al.  From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning. , 2003, Medical physics.